1 / 44

VC Exit Through M&A - Aleksey Krylov

VC Exit Through M&A - Aleksey Krylov

Aleksey
Download Presentation

VC Exit Through M&A - Aleksey Krylov

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. VCEXIT:M&A101 September20,2023 Tialmawww.tialma.com

  2. AlekseyKrylov • 20+yearsofexperience • Tialma,LeadConsultant • FTERAAdvisors,ManagingDirector • Last6years,strategicCFOforVC-backedprivate/publiccompanieswithfocusonstrategictransactions(fundraising,M&A,JV) • 12yearswith4differentfamilyoffices:VC,LBO,structuredanddistressedinvesting:25deals, • $500M+invested • Startedcareerininvestmentbanking • MBAColumbiaBusinessSchool,BSBabsonCollege • aleksey@tialma.com 2

  3. 3 AreteLabscasestudy ExitOptions:M&A TOC BOD LOI AlternativesValuation

  4. Disclaimer Thenumberspresentedinthedeckandthemodelarenottheactualhistoricalnumbersnortheyareprojectednumbersreviewedorendorsedbythecompany Thisexerciseisforillustrativeandeducationalpurposesonly Thisisnotasaleorsolicitationtobuythecompany’ssecurities oritsservices/products 4

  5. CaseStudy:AreteLabs(AL)Business At-homeblood-testingwithpatient-centricdataanalysis Focusonpreventativecare,earlydetection,&chronicdiseasemonitoring Subscription-drivenbusinessmodel 5

  6. CaseStudy:AreteLabs FrankFarlaunchesandinvests $50K(pre-seed,SAFE) $1MSeriesA $50M Purchaseoffer/M&Aexit May2020 Dec.2022 Feb2020 June2021 September2023 $150K SAFE(seed) $6MSeriesB 6

  7. ALFinancialSnapshot $40,000,000 Steadygrowth $35,000,000 $30,000,000 Historicallyprofitable $25,000,000 $20,000,000 Grossprofit~30%as–withinvestmentsincost-down,canreach~60% $15,000,000 $10,000,000 $5,000,000 $0 Cleanbalancesheet/nodebt/noconvertibles 2020A 2021A 2022A 2023E 2024P 2025P 2026P ($5,000,000) Revenue EBITDA

  8. AreteLabsM&AOffer FrankhaddrinkslastnightwithPeter,VPofBDforastrategicbuyer,RipeAid TheyareinterestedinsubmittinganunsolicitedoffertobuytheAreteLabstodayfor$50M FrankhascalledaBoardmeetinglaterthisafternoon ShouldtheBoardsellthecompany? 8

  9. 9 AreteLabscasestudy ExitOptions:M&A TOC BOD LOI AlternativesValuation

  10. Exit M&A IPO Merger Strategicacquisition Secondarysale(PE,blocktrade)LBO/MBO Rollup “Goingprivate” DirectlistingTraditionalunderwrittenIPO Recap ReversemergerSPAC 10

  11. IPO • Somesecuritiesarelistedonanexchange • Mostcommonlycommonstock • Canbedebtorothersecurities • Automaticconversion • Holderssellatwill • Allprefsgointocommon • Upside:Thestockmayrunupfurtherpost-IPO • Downside: • Executionrisk • IPOflatordown • AutomaticconversionONLYinqualifiedfinancing • events(e.g.,sizeorvaluationtriggers) • 11

  12. 12 AreteLabscasestudy ExitOptions:M&A TOC BOD LOI AlternativesValuation

  13. M&A • Acquiror(buyer)takesovercontrolofthe • Target(seller) • Morelikelytobeaprivate/non-transparent • process • WithVC-basedcompanies,trigger • liquidationpreferences • Vestingofoptionsforemployee/execs/BOD • Dependingontheoffer(cashvs.stock),locks • inthereturn 13

  14. Strategics PrivateEquity • Financial&managerialexpertise • Capital • Flexibledealstructure • Leveragemaybeavailable • Focusongrowth • Synergies/highergrowthopportunities • Corporateidentity/mission • Long-termperspective • Accesstoresources • Likelypremiumintheacquisition • Integrationchallenges • Lossofindependence • Inflexibledealterms • Regulatoryhurdle/clearancerisk • Short-termfocus/limitedhorizon • Likelylossofcontrol • Exitpressure • Reorganization/costcutting/layoffs 14

  15. M&A:ComplexEcosystem Regulatory/legal/compliance/documentation Diligence Process Financial:valuation Operations: Post-dealintegration Others? Structuring 15

  16. Legal/SpecialCounsel Players i-bankers AcquirorBODLenders Investors Pubco:arbs TargetMgtteam

  17. Valueoftheseller • Whatisintrinsicvalue? • Discreteviewsonthevalue • Valuationanalyses* • DCF • Comps(trading,deals) • LBO • Sumofparts • Historicalmultiples • Step-up • Premium<>Synergies • Structuring 17 *Notanexhaustivelist

  18. Publicvs.Private Acquirorvs.Target Shareholder approval? Financinginplace? Regulatory approvals? Duediligence Proxyandshareholdervote Tenderoffer,thenacquisition TargetBOD AcquirorBOD Targetshareholders Friendly Hostile Fiduciaryduties/liabilities 18

  19. 3DChess:Regulatory/Legal/Compliance Securitieslaws(federal) Statecorporatelaws(e.g.,Delaware)Exchangerules(e.g.,Nasdaq20%)Common/caselaw IRSregulation/taxation HSR(anti-trust) Othergovreviews:CFIUS+industry-specific 19 Hart-Scott-Rodino CommitteeonForeignInvestmentintheUnitedStates

  20. 20 AreteLabscasestudy ExitOptions:M&A BOD TOC LOI AlternativesValuation

  21. DirectorsHaveFiduciaryDuties PhotobyAlexanderGreyonUnsplash

  22. Reviewandassessthe offer Respondtoit(silenceisaresponse) Documenttheprocess andresolutions(ifany)

  23. $50,000,000 PhotobyAlexanderGreyonUnsplash

  24. DoestheBODneedadvisors? • Legal • Banker • Consulting/accounting/technical • (lesscommon) • Director’sPersonalLiabilityManagement 24

  25. Theformatoftheofferdictatesthe response… • “Let’smeet”–nospecifics • LOI/TermSheet(non-binding):someitemsareclear(e.g.,price,time,process) • Firmcommittedoffer:yay/nay • response 25

  26. 26 AreteLabscasestudy ExitOptions:M&A BOD TOC LOI Alternatives Valuation

  27. LOI • Dividends • Debt • BOD • Operations • Conditionstoclose • Governinglaw • Otherprovisions • Structure • Dealvalue • Earnout(?) • Agreements • Timeline 27

  28. Assessingthequalityoftheoffer? • Structure:Cashvs.stock • Contingencies • Valuation 28

  29. 29 AreteLabscasestudy ExitOptions:M&A BOD TOC LOI Alternatives Valuation

  30. Alternatives • Donothing • Anotherbuyer(strategic)/termsheet • Anotherbuyer/investor(privateequity) • •IPO(S-1/S-4) CanBODquicklygenerateany? 30

  31. $35,000,000 $30,000,000 $25,000,000 $20,000,000 $15,000,000 $10,000,000 $5,000,000 $0 2020A 2021A 2022A 2023E 2024P 2025P 2026P ($5,000,000) Revenue EBITDA Launch+ $50K SeriesB $6M Seed $150K SeriesA $1M Exit???

  32. Preparednessforalternatives RecapPE/VC M&A IPO fundraising • BusinessPlan/Strategy • Pitch • Historicalfinancials(audited) • Projections • Compliance(IP,regulatory,etc.) • Dataroom 32

  33. 33 AreteLabscasestudy ExitOptions:M&A BOD TOC LOI Alternatives Valuation

  34. OpeningOffer $50,000,000 2022 2023 2024 34

  35. Source:https://finviz.comasofSeptember19,2023 35

  36. Unreasonableask? Askformarginscredit(synergies) Askformarketmultiples(15x–20xCF) $80,000,000– $150,000,000 36

  37. ValuationFootballField $167 CFC50%EBITDAx15$133 CFC50%EBITDAx18 $159 $201 CFC50%EBITDAx21 $186 $234 CFC30%EBITDAx15 $82 $106 CFC30%EBITDAx18 $127 $98 CFC30%EBITDAx21 $148 $114 $0 $50 $100 $150 $200$250 Notanunreasonablecounterorvaluationask 37 Currentoffer

  38. StakeholderWaterfall $150,000,000 $150,000,000 $9,000,000 ($2,000,000) ConsiderationCOH Fees $157,000,000 $ (9,366,904.11) SeriesBPref $80,000,000 $147,633,096 ($1,181,260) SeriesAPref ConsiderationCOH Fees $80,000,000 $9,000,000($2,000,000) $146,451,835.62 $(3,246,810.22) $(68,183,016.85) $(54,085,684.38) $(16,234,047.15) ($4,702,276) SeriesSAFEPreferredCommonstock PreferredBasconvertedPreferredAasconverted Options $50,000,000 $87,000,000 $(9,366,904.11) SeriesBPref ConsiderationCOH Fees $50,000,000 $9,000,000($2,000,000) $77,633,096($1,181,260) SeriesAPref $57,000,000(9,366,904.11) $ 76,451,835.62 SeriesBPref $ SeriesSAFEPreferred$Commonstock$PreferredBasconverte$PreferredAasconverte$ (1,694,923.11) (35,593,386.55) (28,234,196.13) (8,474,613.51) $47,633,096 ($1,181,260) SeriesAPref $46,451,835.62 Options ($2,454,716) SeriesSAFEPreferredCommonstock PreferredBasconvertedPreferredAasconvertedOptions $(1,029,828.64) $(21,626,402.13) $(17,154,986.89) $(5,149,141.95) ($1,491,476) $(0.00) Available 38

  39. StakeholderReturns $150,000,000 2/15/2020(50,000)$ 9/20/2023 57,239,027 $ Founder IRRROI 608% 1144.78x $80,000,000 5/15/2020(150,000)$ 9/20/2023 2,435,108 $ 2/15/2020(50,000)$ 9/20/2023 29,880,327 SAFEInvestorsIRR ROI $ 130% 16.23x Founder IRRROI 491% 597.61x $50,000,000 6/15/2021 $(1,000,000)$ 9/20/2023 17,415,307 5/15/2020(150,000)$ 9/20/2023 1,271,192 SeriesAInvestorsIRR ROI $ 2/15/2020(50,000)$ 9/20/2023 18,155,169 253% 17.42x SAFEInvestorsIRR ROI $ 89% 8.47x Founder IRRROI 415% 363.10x 12/15/2022 $(6,000,000)$ 9/20/2023 63,452,588 6/15/2021 $(1,000,000)$ 9/20/2023 9,655,874 SeriesBInvestorsIRR ROI 5/15/2020(150,000)$ 9/20/2023 772,371 2088% 10.58x SeriesAInvestorsIRR ROI $ 172% 9.66x SAFEInvestorsIRR ROI 63% 5.15x 12/15/2022 $(6,000,000)$ 9/20/2023 37,601,100 6/15/2021 $(1,000,000)$ 9/20/2023 6,330,402 SeriesBInvestorsIRR ROI 1003% 6.27x SeriesAInvestorsIRR ROI 126% 6.33x 12/15/2022 $(6,000,000)$ 9/20/2023 26,521,891 SeriesBInvestorsIRR ROI 599% 4.42x 39

  40. PathForward?

  41. WhatShouldtheBoardDo? • Rejectoffer? • Engageinnegotiationtoimproveoffer? • Explorealternatives(otheracquiror?IPO?) 41

  42. ScalingInitiatives • Sales&marketing • Costdowninitiatives • Productlineexpansion • R&D,proprietaryproducts • Geographicreach • M&A • AI Theseusesofcashcreates“drag”onprofitability,sometimeoverthelongterm Quickandsteadyturntoprofitabilityisunusual,especiallyforhigh-growthpotentialbusinesses 42

  43. AnOpinion • Untappedpotentialforthebusiness • Notimetoscale • Incentivesforsomestakeholderstotakethe$whileothersmayprefertostayin • Benefitfromlongertrackrecordofexecution • Approachtonegotiation: • “Goshop”: • Seekalternativebidsfromstrategics • Seekprivateequitypartnerandstructureapartialsalethroughasecondaryandpossiblynewcapitalinvestment • Ofstrategic,aggressivevaluationask(e.g.,$150M)butflexibleontiming • /terms(e.g.,$70Mcashupfront,earnout$50Min2024,$30Min2025) 43

  44. M&AEXIT September20,2023 Tialmawww.tialma.com AlekseyKrylovhttps://alekseykrylov.com

More Related